Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELAB NASDAQ:ENVB NASDAQ:PBLA NASDAQ:PRFX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELABPMGC$2.37+25.4%$2.15$1.81▼$546.00$3.51M0.177.96 million shs158.17 million shsENVBEnveric Biosciences$1.22+5.0%$1.23$1.01▼$8.45$3.97M0.4680,949 shs64,424 shsPBLAPanbela Therapeutics$0.16$0.18$0.05▼$0.47$767K1.3316,227 shs128 shsPRFXPainReform$1.69+3.7%$1.48$1.25▼$16.63$3.40M0.578.61 million shs666,325 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELABPMGC0.00%+22.80%+3.95%+0.85%-99.45%ENVBEnveric Biosciences0.00%+10.91%-6.87%-4.69%-84.80%PBLAPanbela Therapeutics0.00%0.00%0.00%-33.40%-54.23%PRFXPainReform0.00%+25.19%+13.42%-14.21%+58.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELABPMGC0.8764 of 5 stars0.04.00.00.02.80.00.6ENVBEnveric Biosciences1.6026 of 5 stars3.52.00.00.01.10.00.6PBLAPanbela Therapeutics0.321 of 5 stars0.05.00.00.00.60.00.0PRFXPainReform1.2896 of 5 stars0.04.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELABPMGC 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00719.67% UpsidePBLAPanbela Therapeutics 0.00N/AN/AN/APRFXPainReform 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELABPMGC$1.71M2.05N/AN/A$11.53 per share0.21ENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/APBLAPanbela TherapeuticsN/AN/AN/AN/A($18.37) per shareN/APRFXPainReformN/AN/AN/AN/A$2.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELABPMGC-$6.25M-$433.87N/A∞N/AN/A-62.73%-52.83%N/AENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-341.48%-240.71%11/12/2025 (Estimated)PBLAPanbela Therapeutics-$25.26M-$71.13N/A∞N/AN/AN/A-302.61%11/12/2025 (Estimated)PRFXPainReform-$14.59M-$147.33N/A∞N/AN/AN/AN/AN/ALatest PBLA, ENVB, ELAB, and PRFX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ENVBEnveric Biosciences-$5.25-$0.97+$4.28-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELABPMGCN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELABPMGCN/A22.4022.40ENVBEnveric BiosciencesN/A2.422.42PBLAPanbela TherapeuticsN/A0.260.26PRFXPainReformN/A1.811.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELABPMGC22.22%ENVBEnveric Biosciences13.82%PBLAPanbela Therapeutics4.37%PRFXPainReform37.28%Insider OwnershipCompanyInsider OwnershipELABPMGC0.60%ENVBEnveric Biosciences3.20%PBLAPanbela Therapeutics0.01%PRFXPainReform34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELABPMGC181.48 million1.48 millionN/AENVBEnveric Biosciences203.25 million3.14 millionNot OptionablePBLAPanbela Therapeutics64.86 million4.86 millionNot OptionablePRFXPainReform42.01 million1.32 millionNot OptionablePBLA, ENVB, ELAB, and PRFX HeadlinesRecent News About These CompaniesPainReform’s DeepSolar accepted into Nvidia Connect ProgramAugust 19, 2025 | msn.comPainReform’s DeepSolar Joins NVIDIA Connect Program to Enhance Solar ForecastingAugust 19, 2025 | msn.comNvidia enrollment sends this stock soaring 130%August 19, 2025 | finbold.comFTop Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug August 19, 2025 | rttnews.comPainReform Ltd.'s DeepSolar Enters NVIDIA Connect Program to Enhance AI-Driven Solar Forecasting SolutionsAugust 19, 2025 | quiverquant.comQPainReform/DeepSolar Accepted into NVIDIA Connect ProgramAugust 19, 2025 | globenewswire.comPainReform Enters Cataract Surgery Market with LayerBio InvestmentAugust 14, 2025 | msn.comPainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug ...August 13, 2025 | uk.finance.yahoo.comPainReform completes strategic investment in LayerBioAugust 13, 2025 | msn.comPainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery SystemAugust 13, 2025 | globenewswire.comPainreform stock falls after announcing strategic investment in ...July 11, 2025 | investing.comPainReform invests in LayerBio to expand into ophthalmologyJuly 11, 2025 | investing.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand ...July 11, 2025 | seekingalpha.comPainreform stock falls after announcing strategic investment in LayerBioJuly 10, 2025 | au.investing.comPainreform Shares Drop 11% After Revealing Strategic Stake in LayerBioJuly 10, 2025 | msn.comPainReform Expands into Ophthalmology with Strategic Investment in LayerBioJuly 10, 2025 | tipranks.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain ...July 10, 2025 | gurufocus.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain ...July 10, 2025 | gurufocus.comPainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBioJuly 10, 2025 | globenewswire.comBlade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software SalesMay 27, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBLA, ENVB, ELAB, and PRFX Company DescriptionsPMGC NASDAQ:ELAB$2.37 +0.48 (+25.40%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.12 -0.25 (-10.34%) As of 06:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Enveric Biosciences NASDAQ:ENVB$1.22 +0.06 (+5.01%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.21 -0.01 (-0.82%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Panbela Therapeutics NASDAQ:PBLA$0.16 0.00 (0.00%) As of 08/22/2025Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.PainReform NASDAQ:PRFX$1.69 +0.06 (+3.68%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.70 +0.01 (+0.53%) As of 06:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access